Kanada - angol - Health Canada

m & j cosmetics sa - avobenzone; octinoxate; titanium dioxide - lotion - 1.0%; 7.5%; 1.1% - avobenzone 1.0%; octinoxate 7.5%; titanium dioxide 1.1% - sunscreen agents

Nigéria - angol - NAFDAC (National Agency for Food and Drugs Administration and Control)

trichlorocarba-nilide 0.5% w/w

Malajzia - angol - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

alpine medical industries sdn. bhd. - camphor; methyl salicylate; menthol -

Egyesült Államok - angol - NLM (National Library of Medicine)

the procter & gamble manufacturing company - aluminum zirconium tetrachlorohydrex gly (unii: 8o386558je) (aluminum zirconium tetrachlorohydrex gly - unii:8o386558je) - antiperspirant reduces underarm wetness

Egyesült Államok - angol - NLM (National Library of Medicine)

alpine distilling - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antibacterial for rinse free hand cleaning when soap and water are not available.

Egyesült Államok - angol - NLM (National Library of Medicine)

alpine distilling - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antibacterial for rinse free hand cleaning when soap and water are not available.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

colgate-palmolive pty ltd -

Egyesült Államok - angol - NLM (National Library of Medicine)

alpine home medical equipment - oxygen (unii: s88tt14065) (oxygen - unii:s88tt14065) -

Egyesült Államok - angol - NLM (National Library of Medicine)

alpine medical, llc - oxygen (unii: s88tt14065) (oxygen - unii:s88tt14065) -

Szingapúr - angol - HSA (Health Sciences Authority)

abbott medical (singapore), pte. ltd. - cardiovascular - indicated for improving coronary luminal Ø in patients with : • symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. • experiencing ami who present within 12 hrs of symptom onset. • concomitant diabetes, acute coronary syndrome, dual vessel lesions (two lesions in 2 different epicardial vessels), lesions residing within small coronary vessels; lesions where treatment results in jailing of side branches (lesions with a side branch <2mm in Ø or an ostial stenosis <50%); for the treatment of patients (age ≥65), and for treatment of men & women. • in-stent restenosis in coronary artery lesions; cto coronary artery lesions (defined as coronary artery lesions with timi flow 0 and lasting longer than 3 months); and coronary artery bifurcation lesions. in all cases, the treated lesion length should be less than the nominal stent length (8, 12, 15, 18, 23, 28, 33, or 38mm) with a reference vessel Ø of ≥2.00 and ≤4.25 mm.